ArticleAdvances in therapy2024

Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.

Mei Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.